The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Feb 4, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Influenza infection may become complicated in patients with chronic conditions, including coronary artery disease (CAD) \[1\]. Influenza vaccination is now recommended as part of comprehensive secondary prevention in individuals with coronary and other atherosclerotic vascular disease (evidence level: Class I, Level B) \[2\]. Although there is controversial evidence pro \[3,4\] and against \[5\] the efficacy of influenza vaccination in protecting CAD population against cardiovascular events, the efficacy of vaccine in actual reduction in episodes of influenza infection and its fatal complic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Coronary artery disease (CAD) group (CAD-Exp and CAD-Control):
- * Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute phase) as defined by:
- 1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:
- • Ischemic symptoms
- • Development of pathologic Qwaves on the ECG
- • ECG changes indicative of ischemia (ST segment elevation or depression); OR
- * Coronary artery intervention (e.g., coronary angioplasty). 2. Pathologic findings of an acute MI \[1\]:
- • Patients with stable angina pectoris (SA) and documented coronary artery stenosis (angiography).
- • Healthy Control group: healthy controls, proportionally matched by gender and age with the patient group (separate control groups for MI and SA patients).
- Exclusion Criteria:
- • Any acute disease
- • Chronic liver or kidney diseases
- • Conditions accompanied by immunosuppression (like organ transplantation, HIV)
- • Diagnosed malignancy
- • Incubation with influenza vaccine within the past 5 years
- • Any psychological disease that interferes with regular follow-up
- • Congestive heart failure (Killip class IV)
- • Unstable angina; AND
- • Contradictions of vaccine incubation (like egg allergy).
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Maryam Keshtkar-Jahromi, M.D.; M.P.H.
Study Chair
Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Hossein Vakili, M.D.
Principal Investigator
Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Mohammad Rahnavardi, M.D.
Principal Investigator
Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Ali Eskandari, MD
Principal Investigator
Shaheed Beheshti University (MC)
Sharareh Gholamin, MD
Principal Investigator
Shaheed Beheshti University (MC)
Seyed Mostafa Razavi, MD
Principal Investigator
Shaheed Beheshti University (MC)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials